Info@ThinkPinkRocks.org

Actavis plc today announced that it has launched its generic version of AstraZeneca’s Pulmicort RESPULES® (budesonide inhalation suspension) 0.25 and 0.5 mg vials following a ruling from the United States District Court for the District of New Jersey that (i) United States Patent No. 7,524,834 is invalid, and (ii) AstraZeneca’s request for a permanent injunction is denied.

More here:
Actavis releases generic version of Pulmicort RESPULES

Scroll to Top